Home » Newsletters » BioWorld Science

BioWorld Science

May 24, 2007

View Archived Issues

Novel therapeutic agents for obesity described in recent patents

Recent patents impart new anticancer compounds

Novel agents for cardiovascular disorders disclosed in recent patents

Prevention of integrin activation by E-6007 shows benefit in inflammatory bowel disease

Cymbalta shown to improve functioning in GAD patients

Advisory Committee clears pivotal study of Trinam

Trubion expands research agreement with Dyax

Synosia inlicenses new CNS compound to boost pipeline

BioSeek collaborates with Amylin on novel peptide antiinflammatory therapeutics

Contrave begins second phase III study for obesity

New preclinical studies in gastroenterology

Inovio's DNA delivery technology enhances potency of prostate cancer vaccine

SPA reached for second phase III trial of Fampridine-SR

NEJM article suggests rosiglitazone increases risk of heart attack

ThermoDox demonstrates clinical activity in recurrent breast cancer of chest wall

CC-10004 demonstrates activity in psoriasis

Chymase inhibition beneficial in preclinical models of atopic dermatitis

Positive phase I findings for NB-002 lead to phase II study in onychomycosis

Milnacipran shows statistically significant therapeutic effects in fibromyalgia

New clinical data on valopicitabine in hepatitis C presented

Persistent antihypertensive effects of AR-9281 in vivo via soluble epoxide hydrolase inhibition

Arformoterol safe over year in chronic obstructive pulmonary disease

Clinical trials of biologically based therapeutics for asthma

Preclinical evaluation of the novel dual AT1/ETA receptor antagonist PS-433540

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...